Analysis of U.S. Patent 10,398,707: Composition and Method of Treatment
U.S. Patent 10,398,707, granted on September 3, 2019, to Eli Lilly and Company, claims a pharmaceutical composition and a method of treating a disease using an antibody targeting the protein LILRB1 (Leukocyte Immunoglobulin-Like Receptor B1). The patent's scope encompasses specific antibody constructs and their use in modulating immune responses for therapeutic benefit.
What Diseases Does Patent 10,398,707 Address?
The patent primarily targets diseases characterized by an overactive or dysregulated immune response. This includes, but is not limited to, autoimmune disorders and inflammatory conditions. The invention's core mechanism involves blocking the interaction between LILRB1 and its ligands, thereby dampening inhibitory signals within the immune system.
What is LILRB1 and Its Role in Disease?
LILRB1, also known as ILT2 or CD85J, is an inhibitory receptor found on various immune cells, including natural killer (NK) cells, T cells, B cells, and myeloid cells. Its activation by specific ligands leads to suppression of immune cell function. In certain disease states, overexpressed or aberrantly functioning LILRB1 can contribute to immune evasion by pathogens or the unchecked progression of autoimmune attacks.
The patent describes antibodies that bind to LILRB1. This binding can:
- Block the interaction of LILRB1 with its natural ligands.
- Prevent downstream inhibitory signaling cascades.
- Potentially lead to enhanced immune cell activity against disease targets.
What Specific Antibody Constructs Are Claimed?
Patent 10,398,707 discloses a genus of antibodies that bind to LILRB1. The claims define these antibodies based on their amino acid sequences, particularly focusing on the complementarity-determining regions (CDRs) responsible for antigen binding.
Key Claimed Features of the Antibodies
The claims specify structural characteristics of the antibodies, including:
- Variable Region Sequences: The patent delineates specific sequences for the heavy and light chain variable regions. For instance, claims often define antibodies by the CDR sequences of their heavy and light chains (H1, H2, H3, L1, L2, L3). Specific examples of antibody sequences are provided within the patent document to illustrate the claimed invention.
- Binding Affinity: While not always explicitly quantified in the broadest claims, the implied therapeutic utility necessitates high binding affinity to LILRB1.
- Isotype: The patent may specify or broadly claim antibodies of particular isotypes (e.g., IgG1, IgG4) to modulate effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), or to minimize unwanted immune responses.
- Humanization/Chimerization: The patent anticipates or claims humanized or chimeric antibody formats, which are standard in therapeutic antibody development to reduce immunogenicity.
What is the Claimed Method of Treatment?
The patent claims a method of treating a disease by administering an effective amount of the LILRB1-binding antibody. The method involves:
- Identifying a Patient: The patient is typically identified as suffering from a disease where modulation of the LILRB1 pathway is beneficial.
- Administering the Antibody: The antibody composition is administered via a suitable route (e.g., intravenous, subcutaneous).
- Achieving Therapeutic Effect: The administration aims to achieve a therapeutic outcome, such as reducing inflammation, inhibiting autoimmune progression, or enhancing the immune system's ability to clear diseased cells.
Diseases Explicitly Mentioned or Implied
While specific disease names can vary in their breadth within patent claims, the general categories of conditions amenable to LILRB1 blockade are central to the patent's scope. These can include:
- Autoimmune Diseases: Conditions where the immune system mistakenly attacks the body's own tissues.
- Inflammatory Disorders: Chronic or acute conditions characterized by excessive inflammation.
- Cancer: While not the primary focus, modulation of LILRB1 can also be relevant in cancer immunotherapy by overcoming immune suppression in the tumor microenvironment.
What is the Patent Landscape for LILRB1 Inhibitors?
The patent landscape for LILRB1 inhibitors is evolving, with several companies actively developing therapeutics targeting this pathway. U.S. Patent 10,398,707 is one component within this broader competitive space.
Key Players and Their LILRB1-Targeting Programs
- Eli Lilly and Company: Holds U.S. Patent 10,398,707, indicating a foundational interest in LILRB1 as a therapeutic target. Lilly's known programs in immunology and oncology suggest potential applications for this technology.
- Other Pharmaceutical Companies: Several biotechnology and pharmaceutical firms are researching LILRB1 and its ligands for therapeutic intervention. These efforts span various disease indications. Competitive analysis would involve identifying other issued patents and pending applications claiming LILRB1-binding antibodies, related targets, or specific therapeutic uses.
Related Technologies and Targets
The LILRB1 landscape intersects with other immune checkpoint inhibitors and modulation strategies. This includes antibodies targeting:
- PD-1/PD-L1: Well-established immune checkpoints.
- CTLA-4: Another key inhibitory receptor on T cells.
- Other LILR Family Members: LILRB1 is part of a larger family of receptors, and research may extend to other family members.
- Ligands of LILRB1: Antibodies or small molecules targeting the ligands that bind to LILRB1 are also a potential area of development.
Patent Prosecution Trends
Analysis of patent filings related to LILRB1 reveals trends in:
- Breadth of Claims: Companies often seek broad claims initially, which may be narrowed during prosecution.
- Specificity: Later filings might focus on specific antibody sequences, formulations, or disease indications.
- Exclusivity: The granted claims of Patent 10,398,707 provide Eli Lilly with a degree of exclusivity over the specifically defined antibodies and their described uses.
What is the Strategic Significance of Patent 10,398,707?
U.S. Patent 10,398,707 represents a key intellectual property asset for Eli Lilly and Company in the field of immune modulation. Its significance lies in the protection it affords to specific LILRB1-targeting antibody technologies.
Impact on R&D and Investment
- R&D Direction: The patent informs the research and development strategies of competitors. Companies developing LILRB1 inhibitors must carefully navigate the claims of this patent to avoid infringement. This may necessitate developing antibodies with distinct epitopes or different mechanisms of action.
- Investment Decisions: For investors, understanding the scope and strength of patents like 10,398,707 is crucial for assessing the competitive advantage and market potential of companies operating in the LILRB1 space. A strong patent portfolio can deter competitors and secure market exclusivity.
- Licensing and Collaboration: The patent may serve as a basis for licensing agreements or collaborative research initiatives, allowing other entities to utilize the technology under specific terms.
Potential for Market Exclusivity
The claims of Patent 10,398,707, if broadly interpreted and vigorously defended, can grant Eli Lilly a period of market exclusivity for the covered antibody compositions and treatment methods. The duration of this exclusivity is governed by U.S. patent law, typically 20 years from the filing date, subject to potential patent term extensions.
What are the Limitations and Challenges?
Despite the patent's protection, several factors can influence its ultimate commercial impact.
Patent Validity and Enforcement
- Prior Art: The patent's validity can be challenged based on prior art that was not considered during examination.
- Infringement Analysis: Determining infringement requires a detailed comparison of competitor products against the specific language of the patent claims. Competitors may design around the claims by developing antibodies that do not literally fall within the claimed scope.
- Enforcement Costs: Patent litigation is often lengthy and expensive.
Technical and Clinical Hurdles
- Clinical Efficacy and Safety: The ultimate success of any therapeutic antibody depends on its performance in clinical trials, demonstrating both efficacy and an acceptable safety profile.
- Manufacturing and Scalability: Producing therapeutic antibodies at commercial scale presents significant manufacturing challenges.
- Market Competition: The presence of other therapies for the targeted diseases, including other immune modulators, will influence market adoption.
Key Takeaways
- U.S. Patent 10,398,707, owned by Eli Lilly and Company, protects specific antibody compositions that bind to LILRB1 and their use in treating diseases.
- The patent's scope includes antibodies defined by their amino acid sequences, particularly CDR regions, and their application in modulating immune responses for conditions like autoimmune disorders and inflammatory diseases.
- The patent is a significant intellectual property asset, influencing R&D strategies and investment decisions within the competitive LILRB1 inhibitor landscape.
- Potential challenges to the patent's commercial impact include patent validity challenges, infringement complexities, and the rigorous requirements of clinical development and market competition.
Frequently Asked Questions
1. What is the expiration date of U.S. Patent 10,398,707?
The patent was granted on September 3, 2019. Under standard U.S. patent law, it is generally expected to expire 20 years from its earliest U.S. filing date, which would typically be around 2038, although Patent Term Adjustment or Extension could modify this.
2. Does this patent prevent all LILRB1 inhibitors from being developed?
No, the patent protects specific antibody compositions and methods as defined by its claims. Competitors can potentially develop LILRB1 inhibitors that are structurally or functionally distinct from what is claimed in U.S. Patent 10,398,707, provided these new developments do not infringe on the patent's claims.
3. What is the primary therapeutic target of the antibodies claimed in this patent?
The primary therapeutic target is the protein LILRB1 (Leukocyte Immunoglobulin-Like Receptor B1).
4. Can this patent be used to block the development of cancer immunotherapies?
While the patent's primary focus appears to be on autoimmune and inflammatory diseases, LILRB1 also plays a role in immune regulation within the tumor microenvironment. Therefore, the patent could potentially impact LILRB1-targeted cancer immunotherapies if the claimed antibodies or methods are applicable.
5. What is the significance of claims focusing on CDR sequences?
Claims that define antibodies by their Complementarity-Determining Region (CDR) sequences are broad. CDRs are the hypervariable loops of antibodies that directly interact with the antigen. Defining an antibody by its CDRs allows for protection of a family of antibodies that share these critical binding elements, even if other parts of the antibody structure are modified.
Citations
[1] Eli Lilly and Company. (2019). U.S. Patent 10,398,707 B2: LILRB1 BINDING AGENTS AND METHODS OF USE THEREOF. United States Patent and Trademark Office.
